Acquisition opportunity Recent acquisition by Headlands Research in 2021 suggests Artemis Institute for Clinical Research may benefit from enterprise-scale integration, shared services, or expanded site networks. Engage to explore post-acquisition collaboration, standardized processes, and potential cross-sell of trial management capabilities.

Award-winning credibility Pharma Times Site Team of the Year awards in 2020 reinforce Artemis as a high-quality, compliant site with strong performance. Use this strong reputation to open conversations with sponsors seeking reliable, low-variance sites for CNS and medical condition trials.

CNS trial focus Close alignment with central nervous system research and past completion of numerous CNS studies indicate expertise that can be leveraged to win CNS and neurology trial business, including early-phase and late-phase programs requiring careful subject evaluation.

Smaller but agile Company size (11–50 employees) positions Artemis as a nimble partner capable of rapid study setup and close sponsor collaboration. Position offerings around dedicated client attention, faster enrollment decisions, and flexible study management compared to larger CROs.

Regional footprint Based in San Diego with a focus on Southern California and a track record of 213 completed studies and ongoing enrollments as of 2016, there is an opportunity to expand geographic scope through Headlands’ network, offering co-located sites or regional expansion to sponsors seeking diverse patient populations.